

**JAGADISHWAR**

**PHARMACEUTICAL  
WORKS LIMITED**

CIN : L24232WB1987PLC281952

21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

Website: jagadishwarpharma.com

E\_mail ID: [jpwltd@yahoo.com](mailto:jpwltd@yahoo.com)

Phone No.: +91 9163513015

**Date: February 10, 2026**

**Head- Listing & Compliance**

**Metropolitan Stock Exchange of India Ltd. (MSEI),**

205(A), 2nd Floor, Piramal Agastya Corporate Park,

Kamani Junction, LBS Road,

Kurla (West),

Mumbai – 400 070

**Subject: Outcome of Board Meeting held on February 10, 2026- Un-audited Financial Results for the quarter ended December 31, 2025**

Dear Sir,

This is to inform that the Board of Directors of the Company at its meeting held today, i.e. **February 10, 2026**, which commenced at 02.30 p.m. and concluded at 03.00 p.m. has, inter-alia, transacted the following business: -

1. Approved and taken on record the Standalone Un-audited Financial Results along with Limited Review Report of the Company for the quarter ended on December 31, 2025, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. (enclosed herewith)

Kindly take the above information on your record.

Thanking You,

Yours Faithfully,

**For Jagadishwar Pharmaceutical Works Limited**

  


**Swapan Sarkar**

**Director**

**DIN: 05149442**

**Encl: As above**

**Jagadishwar Pharmaceutical Works Limited**

(CIN : L24232WB1987PLC281952)

21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

Email: jpwlttd@yahoo.com, Website: jagadishwarpharma.com, Tel.: +91 9163513015

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025**

(Rs. In Lacs)

	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1</b>	<b>Income From Operations</b>						
	(a) Net Sales / Income from Operations (Net of Excise Duty)	-	5.981	-	5.981	-	-
	(b) Other Operating Income	9.011	9.011	6.568	27.099	18.755	25.080
	<b>Total Income from Operations</b>	<b>9.011</b>	<b>14.992</b>	<b>6.568</b>	<b>33.080</b>	<b>18.755</b>	<b>25.080</b>
<b>2</b>	<b>Expenses</b>						
	(a) Cost of materials consumed	-	5.981	-	5.981	-	-
	(b) Purchase of stock-in-trade	-	-	7.250	-	7.250	12.325
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	(7.250)	-	(7.250)	(12.325)
	(d) Employee benefits expense	7.966	13.034	7.756	28.319	28.116	35.128
	(e) Depreciation and amortisation expense	-	-	-	-	-	0.166
	(f) Other expenses	1.335	1.208	0.931	6.718	6.456	8.674
	<b>Total Expenses</b>	<b>9.301</b>	<b>20.224</b>	<b>8.688</b>	<b>41.019</b>	<b>34.572</b>	<b>43.968</b>
<b>3</b>	<b>Profit / (Loss) from Operations before other income, finance costs and exceptional items (1-2)</b>	<b>(0.290)</b>	<b>(5.231)</b>	<b>(2.120)</b>	<b>(7.939)</b>	<b>(15.817)</b>	<b>(18.888)</b>
<b>4</b>	Other Income	-	-	-	-	-	-
<b>5</b>	<b>Profit / (Loss) from ordinary activities before finance costs and exceptional items (3-4)</b>	<b>(0.290)</b>	<b>(5.231)</b>	<b>(2.120)</b>	<b>(7.939)</b>	<b>(15.817)</b>	<b>(18.888)</b>
<b>6</b>	Finance Costs	-	-	-	-	-	-
<b>7</b>	<b>Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)</b>	<b>(0.290)</b>	<b>(5.231)</b>	<b>(2.120)</b>	<b>(7.939)</b>	<b>(15.817)</b>	<b>(18.888)</b>
<b>8</b>	Exceptional Items	-	-	-	-	-	-
<b>9</b>	<b>Profit / (Loss) from ordinary activities before tax (7-8)</b>	<b>(0.290)</b>	<b>(5.231)</b>	<b>(2.120)</b>	<b>(7.939)</b>	<b>(15.817)</b>	<b>(18.888)</b>
<b>10</b>	Tax Expense	-	-	0.647	-	1.865	-
<b>11</b>	<b>Net Profit / (Loss) from ordinary activities after tax (9-10)</b>	<b>(0.290)</b>	<b>(5.231)</b>	<b>(2.766)</b>	<b>(7.939)</b>	<b>(17.682)</b>	<b>(18.888)</b>
<b>12</b>	Extraordinary items (net of tax Rs. Nil Lakhs)	-	-	-	-	-	-
<b>13</b>	<b>Net Profit / (Loss) for the period (11-12)</b>	<b>(0.290)</b>	<b>(5.231)</b>	<b>(2.766)</b>	<b>(7.939)</b>	<b>(17.682)</b>	<b>(18.888)</b>
<b>14</b>	Share of Profit / (loss) of associates	-	-	-	-	-	-
<b>15</b>	Minority Interest	-	-	-	-	-	-
<b>16</b>	<b>Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13-14-15)</b>	<b>(0.290)</b>	<b>(5.231)</b>	<b>(2.766)</b>	<b>(7.939)</b>	<b>(17.682)</b>	<b>(18.888)</b>
<b>17</b>	Other Comprehensive Income	-	-	-	-	-	12.271
<b>18</b>	<b>Total Comprehensive Income</b>	<b>(0.290)</b>	<b>(5.231)</b>	<b>(2.766)</b>	<b>(7.939)</b>	<b>(17.682)</b>	<b>(6.617)</b>
<b>19</b>	<b>Paid-up Equity Share Capital (Face Value of Rs.10/- per Share)</b>	<b>2,970.019</b>	<b>2,970.019</b>	<b>2,970.019</b>	<b>2,970.019</b>	<b>2,970.019</b>	<b>2,970.019</b>
<b>20</b>	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	138.953
<b>21.i</b>	<b>Earnings Per Share (before extraordinary items) (of Rs. 10/- each) (not annualised)</b>						
	(a) Basic	-	-	-	-	-	-
	(b) Diluted	-	-	-	-	-	-
<b>21.ii</b>	<b>Earnings Per Share (after extraordinary items) (of Rs. 10/- each) (not annualised)</b>						
	(a) Basic	-	-	-	-	-	-
	(b) Diluted	-	-	-	-	-	-

**Notes:**

- The above results have been reviewed by the audit committee and approved by the Board of Directors of the Company in its meeting held on 10/02/2026.
- The standalone financial results of the Company for the quarter and nine months ended 31st December, 2025 have been unaudited by the Statutory Auditors.
- Statutory Auditors have carried out a "Limited Review" of the above financial results for the quarter/nine months ended 31st December, 2025.
- Previous Period / Year figures have been regrouped/reclassified to make them comparable with those of current period/year.

For Jagadishwar Pharmaceutical Works Limited



*Swapan Sarkar*  
Swapan Sarkar  
Director

(DIN: 05149442)

Place : Kolkata  
Date : 10/02/2026



Review report to Jagadishwar Pharmaceutical Works Limited

We have reviewed the accompanying statement of unaudited financial results of Jagadishwar Pharmaceutical Works Limited (Name of the Company) for the period ended 31st December, 2025. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.



For **Rajesh U Shah & Associates**  
Chartered Accountants

  
**Rajesh Shah**

Proprietor

Membership Number: 056550

Firm Regn. No.: 327799E

UDIN: 26056550 FFSYI#5191

Place: Kolkata

Date: February 10, 2026